Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Qinhao Pharmaceutical's Synthetic Lethal Therapy MAT2A Inhibitor GH31 Reaches Global Partnership with Gilead
On February 13th, the Suzhou Industrial Park Science and Technology Investment Promotion Center introduced QinHao Pharmaceutical (Suzhou) Co., Ltd.'s synthetic lethal anti-tumor project GH31 to a global cooperation agreement with Gilead Sciences, Inc. of the United States. According to the terms of the agreement, Gilead will obtain exclusive rights to develop and commercialize GH31 worldwide. QinHao Pharmaceutical will receive an upfront payment of $80 million and is eligible for milestone payments of up to $1.45 billion for development, registration, and commercialization, as well as tiered royalties based on net sales, with a maximum double-digit percentage.